Oligoastrocytomas is a part of a group of brain tumor called
“gliomas”. Glioma tumor is originated in the brain or spine. Oligoastrocytomas
contains both astrocytoma cells and oligodendroglioma. About 2.3% of the brain
tumors reported are diagnosed as oligoastrocytomas. Oligoastrocytomas is
divided into two parts, low grade and anaplastic. According to the WHO grading
system, anaplastic oligoastrocytomas are usually identify as grade 1 and grade
2 but sometimes they appear to be grade 4. Anaplastic oligoastrocytomas
can be characterized by high cellularity, conspicuous cytologic atypism,
microvascular proliferation, mitotic activity and necrosis. Patients
suffering from this condition show symptoms like headache, seizure and speech
or motor changes. According to the American Brain Cancer Association, clinical
trials for the treatment of this tumor are in process to minimize the
recurrence rate of anaplastic oligoastocytoma caused after the surgical removal
of tumor or chemotherapy and radiation therapy session.
Anaplastic oligoastrocytomas market is offers potential
opportunities to cancer care industry. Factors contributing the growth of
anaplastic oligoastrocytomas market are rising geriatric population, increasing
incidence of anaplastic oligoastrocytomas and increasing pace of clinical
trials for novel drug development. Moreover factors such as advancement in
technology and innovations in diangositc techniques is expected to drive the
growth of anaplastic oligoastrocytoma market over the forecast period. However,
lack of specific treatment and critical diagnosis of anaplastic
oligoastrocytoma is the major challenge for anaplastic oligoastrocytomas
market.
For detailed insights on enhancing your product
footprint, request for a Sample here @ https://www.persistencemarketresearch.com/samples/10502
Basically the treatment of anaplastic oligoastrocytoma
depends on the size of the tumor. The treatment is processed by surgery to
remove the tumor. In order to eliminate the cancerous cells, the combinational
therapies such as chemotherapy or radiation therapy are used as effective
treatment for anaplastic oligoastrocytoma.
Anaplastic oligoastrocytoma market is segmented on basis of
treatment Type, end user and region:
- By
Treatment Type
- Chemotherapy
- Radiation
- By
End Use
- Hospitals
- Cancer
Centers
- Surgical
Centers
Oligoastrocytomas is most common in adults and generally
occurs at the age of 35–50. Generally these type of tumors are found in both
the genders. Children of age 0-14 are often diagnosed with oligoastrocytomas
and these tumors comprises of only three percent of primary brain tumors.
Factors such as increasing demand for treatment therapies for anaplastic
oligoastrocytoma, increasing prevalence of anaplastic oligoastrocytoma in
emerging economies are expected provide traction to the growth of anaplastic oligoastrocytoma
over the forecast period (2016-2026)
To receive extensive list of important regions, ask for
TOC here @ https://www.persistencemarketresearch.com/toc/10502
On the basis of region presence, anaplastic oligoastrocytoma
market is segmented into five key regions: North America, Latin America,
Europe, Asia Pacific, and Middle East & Africa. The North America and
Europe market are at maturity level for clinical research of treatment for
anaplastic oligoastrocytomas. Markets of Asia-Pacific region have also shown
keen interest in clinical trials of this tumor and are showing growth at faster
pace, due to increasing incidence of anaplastic oligoastrocytoma.
Following are the companies and institutions which are
involved in clinical trials of treatment for anaplastic oligoastocytomas are:
- Tocagen
- Shandong
Lanjin Pharmaceuticals Co. Ltd
- Keryx
Biopharmaceuticals
- Biogen
Idec
- Insys
Therapeutics
- Rush
University Medical Center
Explore Extensive Coverage of Persistence Market
Research`s Healthcare Landscape
About
us:
Persistence
Market Research, as a 3rd-party research organization, does operate through an
exclusive amalgamation of market research and data analytics for helping
businesses ride high, irrespective of the turbulence faced on the account of
financial/natural crunches.
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com